<DOC>
	<DOCNO>NCT01340664</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 2 different dos canagliflozin compare placebo patient type 2 diabetes mellitus receive treatment metformin monotherapy ( ie , treatment single drug ) inadequate glycemic ( blood sugar ) control .</brief_summary>
	<brief_title>An Efficacy , Safety , Tolerability Study Canagliflozin Treatment Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Metformin Monotherapy</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know identity assign study drug ) , placebo-controlled , parallel-group,3-arm ( 3 treatment group ) multicenter study determine efficacy , safety , tolerability canagliflozin compare placebo ( capsule identical appearance canagliflozin contain active drug ) patient type 2 diabetes mellitus ( T2DM ) achieve adequate response current antihyperglycemic therapy metformin control diabetes . Canagliflozin ( Sodium-Glucose Cotransporter 2 inhibitor ) currently development low blood sugar level patient T2DM . Patients take single-blind placebo capsule orally ( mouth ) 2 week randomization . Patients randomly assign canagliflozin match placebo , orally , twice daily , 1 capsule take morning meal 1 capsule take even meal ( 2 capsule per day ) concurrent metformin , applicable , 18 week . The dosing time metformin remain throughout study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>All patient must diagnosis T2DM currently treat metformin Patients study must HbA1c &gt; =7 &lt; =10.5 % Patients must fast plasma glucose ( FPG ) &lt; 270 mg/dL ( 15 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy , severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>